S. Pierce

发表

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Rashmi Kanagal-Shamanna, Koichi Takahashi, Jorge Cortes, 2016, Cancer.

Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia

Z. Estrov, M. Andreeff, H. Kantarjian, 2018, American journal of hematology.

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Clinical lymphoma, myeloma & leukemia.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Mark Brandt, Susan O'Brien, B Nebiyou Bekele, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Clinical lymphoma, myeloma & leukemia.

Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia.

E. Estey, H. Kantarjian, F. Ravandi, 2007 .

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, American journal of hematology.

Imatinib front‐line therapy is safe and effective in patients with chronic myelogenous leukemia with pre‐existing liver and/or renal dysfunction

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Blood.

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2015, The Lancet. Haematology.

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

H. Kantarjian, S. Pierce, F. Giles, 2007, Cancer.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

Clinical characteristics of Philadelphia positive T‐cell lymphoid leukemias—(De novo and blast phase CML)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, American journal of hematology.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, The Lancet. Haematology.

Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia

H. Kantarjian, J. Cortes, S. Pierce, 2004, Cancer.

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Cancer.

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Cancer.

Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

M. Suarez‐Almazor, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Z. Estrov, H. Kantarjian, T. Manshouri, 2017, Haematologica.

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

M. Cazzola, Z. Estrov, H. Kantarjian, 2012, Blood.

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2009, Blood.

Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2005, Leukemia research.

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelo ﬁ brosis

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021 .

The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study,

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

To the editor: Ventricular arrhythmias and sudden death in patients taking ibrutinib

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2017 .

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Cancer.

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

M. Konopleva, H. Kantarjian, J. Cortes, 2015, The Lancet. Haematology.

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, The Lancet. Haematology.

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Annals of Hematology.

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Blood.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

H. Kantarjian, F. Ravandi, S. Pierce, 2011, Blood.

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2009, Cancer.

Anthracycline dose intensification in adult acute lymphoblastic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Cancer.

Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia

M. Konopleva, H. Kantarjian, K. Patel, 2021, British journal of haematology.

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.

E. Estey, M. Andreeff, H. Kantarjian, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Topotecan a nd C ytarabine I s a n A ctive C ombination Regimen i n M yelodysplastic S yndromes a nd C hronic Myelomonocytic L eukemia

E. Estey, M. Andreeff, H. Kantarjian, 1999 .

FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden

M. Konopleva, H. Kantarjian, K. Patel, 2021, American journal of hematology.

The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

E. Estey, H. Kantarjian, J. Cortes, 2008, Clinical Cancer Research.

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Leukemia research.

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

M. Konopleva, H. Kantarjian, J. Cortes, 2013, Leukemia research.

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2011, Blood.

MYELOID NEOPLASIA Correlation of mutation pro ﬁ le and response in patients with myelo ﬁ brosis treated with ruxolitinib

H. Kantarjian, J. Cortes, T. Manshouri, 2015 .

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy

M. Cazzola, Z. Estrov, H. Kantarjian, 2011 .

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

H. Kantarjian, J. Cortes, S. Verstovsek, 2016, British journal of haematology.

Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trials

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Haematologica.

Quantifying the Survival Benefit for Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia

F. Ravandi, S. Pierce, M. Lima, 2014 .

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2010, Cancer.

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2002, Leukemia research.

Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection.

G. Garcia-Manero, Koichi Takahashi, S. Pierce, 2012, Leukemia research.

Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment

G. Garcia-Manero, K. Patel, T. Kadia, 2022, American journal of hematology.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2014, Clinical lymphoma, myeloma & leukemia.

Cause of death in patients with lower‐risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Cancer.

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, J. Maciejewski, 2011 .

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival

Yu Shen, H. Kantarjian, S. Pierce, 2001, Leukemia & lymphoma.

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Leukemia & lymphoma.

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Front. Oncol..

Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients

G. Garcia-Manero, K. Patel, T. Kadia, 2022, American journal of hematology.

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2005 .

Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2011 .

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, American journal of hematology.

Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012, British journal of haematology.

Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS)

K. Do, H. Kantarjian, G. Garcia-Manero, 2021, American journal of hematology.

Predicting survival of patients with hypocellular myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, A. Quintás-Cardama, 2012, Cancer.

Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2018, Blood.

Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2022, Leukemia & lymphoma.

A randomized phase II trial of 5-day versus 10-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia

Farhad, Z. Estrov, H. Kantarjian, 2019 .

Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia

G. Garcia-Manero, J. Cortes, T. Kadia, 2017 .

Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.

G. Garcia-Manero, G. Borthakur, S. Pierce, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

H. Kantarjian, G. Garcia-Manero, G. Borthakur, 2008 .

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, American journal of hematology.

Clinical value of event-free survival in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.

G. Garcia-Manero, E. Shpall, T. Kadia, 2022, The Lancet. Haematology.

CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?

J. Byrd, E. Estey, R. Howard, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012, American journal of hematology.

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Therapeutic advances in hematology.

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood Cancer Journal.

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Blood.

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, J. Cortes, 2004 .

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

P. Sharma, M. Konopleva, M. Andreeff, 2016 .

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Susan O'Brien, Jorge Cortes, E. Estey, 2006, Cancer.

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014, Leukemia research.

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.

Ken H. Young, Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, 2015, Leukemia research.

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

H. Kantarjian, J. Cortes, G. Borthakur, 2008 .

Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Comorbidities and Myelodysplatic Syndromes.

M. Suarez‐Almazor, G. Garcia-Manero, S. Pierce, 2009 .

Biphenotypic acute leukaemia: a case series

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007, British journal of haematology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Prospective Feasibility Analysis of Reduced Intensity Conditioning Regimens (RIC) for Hematopoietic Stem Cell Transplantation (HSCT) in Elderly Patients with AML and MDS.

E. Estey, S. Pierce, R. Tibes, 2005 .

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CR1) Post Induction Chemotherapy: a Retrospective Case Control Study.

H. Kantarjian, F. Ravandi, G. Borthakur, 2008 .

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004, Leukemia research.

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2008, Leukemia research.

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Leukemia & lymphoma.

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case–control study

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome

M. Konopleva, K. Rezvani, H. Kantarjian, 2018, Clinical lymphoma, myeloma & leukemia.

Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

Z. Estrov, M. Andreeff, H. Kantarjian, 2013, British journal of haematology.

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Jorge Cortes, Guillermo Garcia-Manero, E. Estey, 2007, Blood.

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2016, Leukemia.

TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation

K. Patel, F. Ravandi, S. Pierce, 2013, Modern Pathology.

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

E. Estey, G. Garcia-Manero, S. Verstovsek, 2007 .

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2019, Blood.

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission

H. Kantarjian, E. Shpall, K. Patel, 2022, American journal of hematology.

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Bob Löwenberg, Elihu H. Estey, Megan Othus, 2014, Leukemia.

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Philip R. Cohen, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.

M. Konopleva, H. Kantarjian, J. Cortes, 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

S. Parmar, M. Estecio, H. Kantarjian, 2013, Leukemia.

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

H. Kantarjian, R. Luthra, K. Patel, 2012, Cancer.

Impact of age on outcome of pediatric acute myeloid leukemia

C. Pui, E. Estey, H. Kantarjian, 2006, Cancer.

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin

M. Konopleva, M. Andreeff, H. Kantarjian, 2012, Cancer.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

C. Steidl, F. Solé, M. L. Le Beau, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Blood.

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high‐dose cytarabine chemotherapy

H. Kantarjian, F. Ravandi, S. Pierce, 2009, Cancer.

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Blood.

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

M. Konopleva, J. Cortes, T. Kadia, 2021, Journal of Hematology & Oncology.

A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission.

S. Jagannath, A. Zander, L. Peters, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes

R. Chen, G. Garcia-Manero, C. Dinardo, 2013, PloS one.

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Z. Estrov, M. Andreeff, K. Bhalla, 2019, Leukemia & lymphoma.

Primary refractory and relapsed adult acute lymphoblastic leukemia

Terry L. Smith, J. Cortes, S. Pierce, 1999, Cancer.

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, International Journal of Hematology.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.

P. Thall, E. Estey, H. Kantarjian, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

precursor B-lineage acute lymphoblastic leukemia Prognostic significance of CD 20 expression in adults with de novo

H. Kantarjian, J. Cortes, S. Verstovsek, 2009 .

Prognostic significance of CD 20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Treatment of core‐binding‐factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony‐stimulating factor results in improved event‐free survival

E. Estey, H. Kantarjian, G. Garcia-Manero, 2008, Cancer.

A prognostic score for patients with lower risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2008, Leukemia.

Outcome of patients with acute myelogenous leukemia after second salvage therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005, Cancer.

Granulocyte colony‐stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission

E. Estey, E. Anaissie, H. Kantarjian, 1993, Cancer.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Blood advances.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Blood.

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

H. Kantarjian, J. Cortes, F. Ravandi, 2015, Cancer.

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

E. Estey, Y. Oki, H. Kantarjian, 2006, Blood.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients.

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, International journal of molecular sciences.

Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.

Kohzoh Imai, Minoru Toyota, Guillermo Garcia-Manero, 2003, Blood.

Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

J. Issa, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-κB Activation and Enhances Erythroid Differentiation Arrest

G. Calin, G. Garcia-Manero, S. Pierce, 2014, PloS one.

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

E. Estey, H. Kantarjian, S. Pierce, 2007, Blood.

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Blood.

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2021, Haematologica.

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, American journal of hematology.

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

V. Baladandayuthapani, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

M. Konopleva, H. Kantarjian, J. Cortes, 2015 .

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.

M. Konopleva, Z. Estrov, M. Andreeff, 2016, Clinical lymphoma, myeloma & leukemia.

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, The Lancet. Haematology.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia.

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2015, Leukemia.

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, S. Verstovsek, F. Ravandi, 2009, Cancer.

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Cancer.

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison.

H. Kantarjian, F. Ravandi, E. Jabbour, 2013 .

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care.

Daniel Gomez, Lynda Chin, Koichi Takahashi, 2018, The oncologist.

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

R. Chen, Z. Estrov, H. Kantarjian, 2013, American journal of hematology.

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Z. Estrov, G. Garcia-Manero, J. Cortes, 2009 .

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2009 .

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

H. Kantarjian, G. Garcia-Manero, A. Tsimberidou, 2007 .

61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020

Marina, M. Andreeff, H. Kantarjian, 2020, Indian Journal of Hematology and Blood Transfusion.

PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.

E. Estey, M. Konopleva, M. Andreeff, 2004, Blood.

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012 .

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020 .

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

H. Kantarjian, S. Verstovsek, E. Jabbour, 2016 .

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2019, Blood.

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Leukemia research.

Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Effectiveness of Radiation Treatment in Adult Patients With Mediastinal T Cell Lymphoblastic Leukemia/Lymphoma

O. Mawlawi, E. Jabbour, S. Pierce, 2016 .

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study

M. Konopleva, H. Kantarjian, J. Cortes, 2018, Blood.

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, American journal of hematology.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Hannah C. Beird, M. Konopleva, H. Kantarjian, 2019, Blood.

Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology/oncology.

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Hui Yang, Simona Colla, Xuelin Huang, 2016 .

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

The Predictive Value of a “Positive” ASH Abstract in AML Therapeutics.

E. Estey, S. Pierce, F. Giles, 2006 .

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

P. Sharma, M. Konopleva, M. Andreeff, 2020 .

Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index

M. Suarez‐Almazor, H. Kantarjian, G. Garcia-Manero, 2010 .

Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017 .

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2017 .

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016 .

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.

E. Estey, R. Hills, F. Appelbaum, 2013, Blood.

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

P. Sharma, M. Konopleva, Z. Estrov, 2017 .

Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.

J. Issa, H. Kantarjian, J. Cortes, 1999, Blood.

Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, Leukemia.

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2019, Blood.

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

M. Andreeff, H. Kantarjian, J. Cortes, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, S. Pierce, 1995, Blood.

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

H. Kantarjian, J. Cortes, S. Verstovsek, 2009 .

Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations

G. Garcia-Manero, G. Borthakur, C. Dinardo, 2023, Leukemia.

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

E. Estey, F. Appelbaum, H. Kantarjian, 2012 .

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Z. Estrov, G. Garcia-Manero, J. Cortes, 2013, Leukemia.

era: analysis of patient from six trials.

M. Konopleva, P. Jain, F. Ravandi, 2016 .

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

P F Thall, P. Thall, E. Estey, 1999, Blood.

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells

D. Neuberg, B. Ebert, R. Chen, 2013, Leukemia.

Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2016 .

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

H. Kantarjian, S. Pierce, S. Kornblau, 1996, Blood.

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

E. Estey, M. Andreeff, S. Arbuck, 1996, Blood.

Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.

P. Thall, E. Estey, H. Kantarjian, 1997, Blood.

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2018, Blood.

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.

E. Estey, R. Kurzrock, H. Kantarjian, 1994, Blood.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.

P. Thall, E. Estey, H. Kantarjian, 2001, Blood.

Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.

E. Estey, H. Kantarjian, S. Pierce, 1997, Blood.

Plausibility of Delaying Induction Therapy in Untreated AML.

P. Thall, E. Estey, H. Kantarjian, 2004 .

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Blood.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2015, Leukemia research.

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, Leukemia.

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2014, Leukemia.

Risk factors of myelodysplastic syndromes: a case–control study

E. Estey, S. Pierce, S. Strom, 2005, Leukemia.

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016 .

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

M. Konopleva, Z. Estrov, H. Kantarjian, 2009 .

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

P. Qiu, M. Konopleva, M. Andreeff, 2016, American journal of hematology.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients.

H. Kantarjian, S. Pierce, S. Giralt, 1994, The American journal of medicine.

Treatment of myelodysplastic syndromes with AML-type chemotherapy

M. Andreeff, H. Kantarjian, S. Pierce, 1993 .

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Z. Estrov, H. Kantarjian, T. Manshouri, 2017, Haematologica.

The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2020 .

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2020 .

Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS

Jianhua Zhang, H. Kantarjian, G. Garcia-Manero, 2015 .

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.

E. Estey, H. Kantarjian, S. Pierce, 1993, The American journal of medicine.

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

E. Estey, H. Kantarjian, J. Cortes, 2012 .

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2014, Leukemia.

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

E. Estey, H. Kantarjian, S. Pierce, 2007, Blood.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia.

Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Blood.

Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy

S. Pierce, S. Mackay, J. Matthews, 2024, Cancer research communications.

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

E. Estey, F. Appelbaum, H. Kantarjian, 2014, Leukemia.

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

S. Faiz, G. Garcia-Manero, T. Kadia, 2023, Frontiers in immunology.